| Project/Area Number |
04454409
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | School of Medicine, Keio University |
|---|
Principal Investigator |
TACHIBANA Masaaki Keio Univ., Dept.of Urology, Assistant Professor, 医学部, 講師 (70129526)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAKWA Harumi Keio Univ., Dept.of Urology, Assistant, 医学部・泌尿器科, 助手 (40239356)
YOSHIOKA Kunihiko Keio Univ., Dept.of Urology, Assistant, 医学部・泌尿器科, 助手 (60220589)
NAKASHIMA Jun Urawa Municioal Hosp.Urology, Chief Doctor, 泌尿器科, 医長 (10167546)
TAZAKI Hiroshi Keio Univ., Dept.of Urology, Professor, 医学部・泌尿器科, 教授 (90051268)
実川 正道 浦和市立病院, 泌尿器科学, 部長 (00101957)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Project Status |
Completed (Fiscal Year 1994)
|
| Budget Amount *help |
¥6,100,000 (Direct Cost: ¥6,100,000)
Fiscal Year 1994: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1993: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1992: ¥4,200,000 (Direct Cost: ¥4,200,000)
|
|---|
| Keywords | Bladder cancer / Flow cytometry / DNA ploidy / Bromodeoxyuridine / Tumor invasiveness / Prognostic factor / 泌尿器科腫瘍 / 浸潤性判定 |
|---|
| Research Abstract |
In as much as urotherrial cancer consists of a spectrum of diseases with diverse natural histories, the conventional morphological classifications provided by classical histology still remain the hallmarks in the decisionmaking process. In the present study, an attempt was made to develope the objective and quantitative parameter for determination of malignant potential of bladder cancer. We have found that flow cytometric deoxyribonucleic acid(DNA)/bromodeoxyuridine bivariate analysis can provide important information on the malignant potential of bladder cancer. Also was found that the proliferative rate of the tumor cells in tumor may have significant importance since the rate of DNA synthesis is directly rerated to the rate of tumor growth or to tumor involvement. Then, we have formulated a new grading system based on the histological grade and tumor proliferative activity determinated by the BrdU labeling index. Each tumor was given a score ranging from 1 to 52. Fourty-four patients with a score of 1 demonstrated a 100% three-year survival rate, compared to 42.9% for patients having a score greater than 1. Conversely, 26 patients with the highest score of 52 presented a three-year survival rate of 17.3%. These results suggest that the new grading system can be used as an indicator in decision-making or treatment choice of transitional cell carcinoma of the bladder.
|
